GHK-Cu vs BPC-157
GHK-Cu and BPC-157 are both unapproved peptides discussed in tissue-repair research, but they differ in size, origin and the kind of evidence available 1,5. GHK-Cu is a copper complex of a tripeptide found in human plasma and is used in cosmetic products, while BPC-157 is a 15-residue synthetic peptide studied mostly in rats 1,5. Both have been considered by FDA for the 503A compounding bulks list, and their regulatory paths diverged in 2026 7,8,9.
Side by side
| Field | GHK-Cu | BPC-157 |
|---|---|---|
| Class | Copper-binding tripeptide (Gly-His-Lys with copper) 1 | Synthetic pentadecapeptide 5 |
| Origin and structure | GHK occurs in human plasma, saliva and urine and declines with age 1 | 15 residues (GEPPPGKPADDAGLV), described as a stable gastric pentadecapeptide 5 |
| Proposed mechanism | Reported in lab systems to stimulate synthesis and breakdown of collagen and glycosaminoglycans and to modulate metalloproteinases 1 | Not established; FDA states molecular targets have not been identified 7 |
| Half-life | Not identified in the sources reviewed | FDA found no human pharmacokinetic data after oral, subcutaneous, nasal or transdermal use 7 |
| Highest human trial phase | Small topical studies 3 | Small uncontrolled pilot reports and an abstract-only randomized study described by FDA 7 |
| FDA status | Not approved; non-injectable routes are in 503A category 1 (under evaluation) as of May 2026; injectable GHK-Cu is on FDA's significant-safety-risk page as a withdrawn nomination 8,9 | Not approved; on FDA's significant-safety-risk page as a withdrawn nomination; reviewed by FDA's advisory committee in July 2026 7,9 |
| Published human outcomes | In 13 people after CO2 laser resurfacing, blinded evaluators found no significant difference with a GHK-Cu regimen 3 | Small uncontrolled reports; a systematic review counted 1 clinical study among 36 included 7,6 |
| Safety signals | FDA cites immunogenicity risk for injectable GHK-Cu and limited human data 9 | FDA cites immunogenicity and impurity concerns and insufficient clinical safety information 7,9 |
| WADA status | Not named in the 2026 List 10 | Named in S0 (non-approved substances); prohibited at all times 10 |
| Evidence level | Cell, animal and small topical human studies; a 2026 review called clinical evidence sparse 1,2,3 | Mostly rodent and cell studies; very small human reports 5,6,7 |
GHK-Cu: what the data says
GHK is a tripeptide present in human plasma, saliva and urine whose levels decline with age, and it is proposed to act as a complex with copper(II) in wound healing and skin repair 1. In lab systems it has been reported to stimulate synthesis and breakdown of collagen and glycosaminoglycans and to modulate metalloproteinases and their inhibitors 1. A 2026 evidence-mapping review found preclinical support for matrix remodeling and repair but described clinical evidence as sparse and not meeting current active-entity quality standards 2.
In a randomized study of 13 people after CO2 laser resurfacing, blinded evaluators found no statistically significant difference between GHK-Cu and comparator skin-care regimens 3. In rats, intra-articular GHK-Cu improved knee laxity at 6 weeks after ACL reconstruction but not at 12 weeks, and in rabbits topical tripeptide-copper was compared with zinc oxide and no treatment in open wounds (animal data) 4,11.
BPC-157: what the data says
BPC-157 is a 15-amino-acid peptide described as a stable gastric pentadecapeptide 5. In rats with transected Achilles tendons it was associated with better biomechanical, functional and microscopic recovery than saline, and in chick, cell and rat ischemia models it was associated with VEGFR2 up-regulation and angiogenesis (animal and cell data) 5,12. A 2025 systematic review of orthopaedic sports-medicine uses included 36 studies, 35 of them preclinical 6.
FDA's 2026 briefing for its advisory committee found no human pharmacokinetic data for oral, subcutaneous, nasal or transdermal use, stated that molecular targets have not been identified, and noted no approved BPC-157 product in any country 7.
Key research differences
- Natural occurrence: GHK is found in human plasma, whereas BPC-157 is a synthetic sequence described as derived from a gastric protein 1,5.
- Use context: GHK-Cu appears in cosmetic products and its human data are mostly topical, while BPC-157 human reports involve injected or infused material 1,7.
- Regulatory path: FDA returned non-injectable GHK-Cu to category 1 (under evaluation) in May 2026, while BPC-157 underwent a July 2026 advisory committee review 7,8.
- Mechanism: matrix-remodeling and gene-expression effects have been described for GHK in lab systems, while FDA states that BPC-157's molecular targets are unknown 1,7.
- Sport: BPC-157 is named in WADA's S0 class; GHK-Cu is not named on the 2026 List 10.
Where the evidence is limited
No study comparing GHK-Cu and BPC-157 was identified. GHK-Cu human data are small and mostly topical, and its copper occupancy and formulation are often poorly characterized, which limits comparison across studies 2,3. BPC-157 evidence is mainly from rodents and very small uncontrolled human reports 6,7. Animal findings for either peptide have not been confirmed in controlled human trials.
Frequently asked questions
Is GHK-Cu a natural peptide?
What human data exist for each?
How does FDA treat them for compounding?
Have they been compared directly?
References
- GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration BioMed Research International. 2015
- GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap Pharmaceutics. 2026
- Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin Archives of Facial Plastic Surgery. 2006
- Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction Journal of Orthopaedic Research. 2015
- Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth Journal of Orthopaedic Research. 2003
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review HSS Journal. 2025
- FDA Briefing Document: BPC-157-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026 FDA. 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (categories 1, 2 and 3; updated May 14, 2026) FDA. 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026) FDA (Human Drug Compounding). 2026
- International Standard: Prohibited List 2026 WADA. 2026
- Evaluation of the effects of topical tripeptide-copper complex and zinc oxide on open-wound healing in rabbits Veterinary Dermatology. 2006
- Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation Journal of Molecular Medicine. 2017
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement. This page compares published research and is not medical advice or a recommendation.